Global Embryo Decision Support Tools Market Growth (Status and Outlook) 2025-2031

The global Embryo Decision Support Tools market size is predicted to grow from US$ 44.8 million in 2025 to US$ 60.6 million in 2031; it is expected to grow at a CAGR of 5.2% from 2025 to 2031.

Embryo Decision Support Tools are AI-driven or algorithm-based systems that assist embryologists and fertility specialists in selecting the best embryos for implantation during in vitro fertilization (IVF). These tools enhance accuracy, objectivity, and efficiency in embryo grading and selection, increasing the chances of successful pregnancy.

United States market for Embryo Decision Support Tools is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Embryo Decision Support Tools is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Embryo Decision Support Tools is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Embryo Decision Support Tools players cover Vitrolife, Genea BIOMEDX, MIM Fertility, Alife Health, Fairtility, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Embryo Decision Support Tools Industry Forecast” looks at past sales and reviews total world Embryo Decision Support Tools sales in 2024, providing a comprehensive analysis by region and market sector of projected Embryo Decision Support Tools sales for 2025 through 2031. With Embryo Decision Support Tools sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Embryo Decision Support Tools industry.

This Insight Report provides a comprehensive analysis of the global Embryo Decision Support Tools landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Embryo Decision Support Tools portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Embryo Decision Support Tools market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Embryo Decision Support Tools and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Embryo Decision Support Tools.

This report presents a comprehensive overview, market shares, and growth opportunities of Embryo Decision Support Tools market by product type, application, key players and key regions and countries.

Segmentation by Type:
Web-based
Cloud-based

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vitrolife
Genea BIOMEDX
MIM Fertility
Alife Health
Fairtility
ASTEC CO., Ltd
Care Fertility
Cycle Clarity
KritiKal Solutions
ImVitro

Please note: The report will take approximately 2 business days to prepare and deliver.